Nephron Pharmaceuticals Corporation Recognized in 2024 RXinsider Pharmacy500

June 27, 2024

West Columbia, SC, June 26, 2024 – Nephron Pharmaceuticals Corporation is proud to announce its inclusion in the prestigious 2024 RXinsider Pharmacy500 list, an accolade recognizing the top 500 supply chain companies that have significantly impacted the U.S. dispensing pharmacy landscape.

“We are honored to be recognized by RXinsider for our contributions to the pharmaceutical industry,” said Lou Kennedy, CEO of Nephron Pharmaceuticals. “This acknowledgment underscores our commitment to a quality first culture marked by transformation, execution, and trust.”

Since launching its first inhalation product in 1997, Nephron Pharmaceuticals has grown into one of the largest blow-fill-seal (BFS) manufacturers in the world, producing respiratory, injection, and ophthalmic medications. The company has expanded its capabilities to include 503B outsourcing services, providing critical product to hospitals and surgery centers across the nation. Nephron maintains the same rigorous quality standards across both divisions, which are housed under one roof in its 840,000 square foot cGMP facility in West Columbia, South Carolina.

Nephron Pharmaceuticals is committed to addressing drug shortages and providing high-quality medications to patients. The company’s inclusion in the Pharmacy500 list is a testament to its ongoing efforts to support the pharmacy community and improve healthcare outcomes.

For more information about Nephron Pharmaceuticals and its products, please visit

About Nephron Pharmaceuticals Corporation: Founded in 1997, Nephron Pharmaceuticals Corporation is a leading manufacturer of generic inhalation solutions and suspension products. The company is headquartered in West Columbia, SC, and is dedicated to improving patient access to affordable, high-quality medications. Nephron also provides 503B outsourcing services to ensure the availability of critical medications.